The global sales of neurology digital therapeutics are estimated to be worth USD 245.4 million in 2024 and anticipated to reach a value of USD 496.4 million by 2034. Sales are projected to rise at a CAGR of 8.2% over the forecast period between 2024 and 2034. The revenue generated by neurology digital therapeutics in 2023 was USD 226.8 million.
The growing of neurological disorders is one of the reasons for burden on the public health around the world. Neurological conditions like Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis have taken over the lives of so many people globally, moreover this number is predicted to grow gradually owing to the reasons includes aging population, changing lifestyle, and improving diagnostic capabilities.
Consequently, the need for effective, accessible, and non-invasive treatment options has increased, thereby positioning digital therapeutics as a potential solution to the management of these complex diseases.
Global Neurology Digital Therapeutics Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 226.8 million |
| Estimated Size, 2024 | USD 245.4 million |
| Projected Size, 2034 | USD 496.4 million |
| Value-based CAGR (2024 to 2034) | 8.2% |
Digital therapeutics are defined as a group of evidence-based treatments that use software to treat, manage and/or prevent a wide variety of medical concerns. In a large what, these therapies use digital modalities, such as mobile apps, wearables, and the internet, have evidence-based therapies supported by clinical trials to produce patient outcome measures.
Neurology is potentially one of the largest beneficiaries of digital therapeutics based on the need for new ways of addressing the overwhelming number of complex chronic conditions.
For example, in parkinson’s disease such activity can be remotely monitored via wearable sensors and patter of movement to provide evidence of early signs of dyskinesia. In alzheimer’s disease again, using digital means to track cognitive decline can provide real-time opportunities for timely interventions based on results that ultimately result in cognitive decline at outcomes.
Neurologic disorders are age associated. The World Health Organization (WHO) in their 2022 report, estimates that by 2030, 1 in 6 people will become aged 60 years and older across the globe. At that time the share of individuals who are aged 60 years and older will be over 1 billion which will increase from 2020 which is about 1.4 billion by 2030.
The number of people will double by 2050 at 2.1 billion citizens aged 60 years and older. Today, as a story of numbers, the number of people aged 80 years and older will triple to approximately 426 million globally, between 2020 and the year 2050.
Digital therapeutics afford the opportunity for continuous monitoring of activity and symptoms via wearables and mobile devices. Then these provide neurological information to continually update health care providers regarding progress of the brain disorder allowing for timely adjustment of the treatment program.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Adoption of Mobile Health (mHealth) Applications as Significant Driving Force for Neurology Digital Therapeutics Market
The mHealth applications are revolutionizing neurological conditions are managed, providing patients and healthcare providers with convenient, accessible, and scalable solutions. Due to the easy availability of smartphones, mobile health applications have now become easily accessible to millions of individuals throughout the world.
Most neurological patients face difficulties in receiving continuous care, particularly those living in remote or underserved areas. Mobile health applications are allowing access to various treatments and monitoring of symptoms and conditions while one sits in the comfort of home without frequent visits to healthcare providers.
Mobile Health applications and services are becoming increasingly efficient and thereby providing access to various therapeutic interventions. These include cognitive behavioral therapy (CBT) for neurological conditions such as depression and anxiety that usually occur comorbid with neurological diseases. Structured CBT programs are provided through the apps, which patients might follow either independently or under the guidance of a therapist.
The FDA SaMD Database reports that over 70 mobile health applications and digital therapeutics have been cleared and approved by the FDA under the SaMD framework for use in the treatment of various health conditions, such as chronic diseases, neuropsychiatric disorders, and neurological diseases.
In conclusion, coupled with better patient outcomes, more adoptions od mHealth apps are leading to the contours of change in healthcare that will spur growth in the expansion of DTx in neurology.
Wearable Devices Is Transforming the Neurology Digital Therapeutics
Digital wearables provide for the continuous and real-time monitoring of a patient's physiological and behavioral data. Considering neurological disorders-most of which require ongoing management and real-time insights into symptoms-wearable technology is one of the disruptive technologies in care delivery.
Wearable devices integrated into digital neurology therapeutics ensure more accurate data intake, allow the detection of disease at an earlier stage, and involve more engaged patients in personalized treatment for their specific case.
Wearables can track seizure activity, seizure triggers, and medication adherence among individuals with epilepsy. This information might be used to tailor treatment approaches through personalized suggestions for lifestyle changes, medication adjustments, or behavioral interventions in hopes of decreasing seizure burden.
Likewise, in patients with Parkinson's disease, such wearable information may be analyzed and medication dosages or timing adjusted to better manage motor symptoms throughout the day.
Inclusion of wearables in digital therapeutic programs empowers patients to be more active participants in their care. Wearables can also provide many forms of feedback to the patient in real-time, such as daily activity levels, sleep patterns, and even medication reminders for engagement in their treatment.
This, in turn, helps retain some level of autonomy for the patients in disorders like Alzheimer's disease or dementia and, thereby, improves overall engagement in the management of their condition.
The trend of digital wearable devices has reincarnated the neurology digital therapeutics market by continuous, real-time data, better engagement, and personalized care for the patients.
Reduced Reliance on Pharmacological Interventions Emerging Driver for the Neurology Digital Therapeutics Market
The shift from pharmacological treatments to digital therapeutics is fast becoming one of the critical drivers in the growth of the neurology digital therapeutics market. Pharmacological interventions for neuropathic pain is a major treatment followed, however, they present serious challenges.
By introducing digital therapeutics, patients could reduce or abandon dependence on pain medications altogether. Studies have indeed shown that a combination of CBT, meditation, and physical therapy can be successfully conducted through digital platforms to significantly decrease a patient's need for opioids or other pain-relief drugs. The reduced dependence on pharmacological treatments has a number of other health benefits.
For conditions like, pain after a stroke or injury to the spinal cord, have virtual sessions of physical therapy with the intervention of digital therapeutics. These could be customized to meet the needs of a particular patient based on his or her requirement and modified in real time as the patient's progress might change, to help manage pain with movement and exercise.
Digital therapeutics requirement for neuropathic pain management would grow steeply in the near future as health systems gear up more and more toward non-pharmacological interventions.
Data Privacy and Security Concerns Arises as A Upcoming Challenge for Digital Therapeutics
Treatment by digital therapeutics requires continuous collection, storage, and processing of sensitive health data; hence, neurologic conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy have a related need for effective treatment with regard to comprehensive detail.
However, in the face of growing risks associated with cybersecurity breach, data theft, and possible misuse of the data, patients suffering from neurological disorders are getting skeptical over sharing personal health information. Thus, data privacy concerns become sa key restraint to wider adoption in the neurology market.
Conversely, most neurological disorders necessitate the collection of sensitive data regarding cognitive metrics, emotional well-being, brain activity, and motor functions. Such information is indeed acquired through wearable devices, smartphone applications, or even cloud-based platforms. While such in-depth health information is a prerequisite for personalized therapeutic intervention, it certainly challenges the patient's private life.
According to IBM’s Cost of a Data Breach Report (2022), the average cost of a healthcare data breach reached an all-time high of USD 10.1 million per incident in 2022, a significant increase from previous years.
A report by Sophos-the State of Ransomware in Healthcare 2022-reveals that 66% of healthcare organizations globally were attacked by ransomware in 2021, against 34% in 2020, a factor that further underlines the increasing threat that cybersecurity attacks pose to sensitive health data.
Key legislation and acts that govern data privacy and security include. General Data Protection Regulation (GDPR) one of the most far-reaching laws with regard to data protection in the world, the GDPR aims to protect personal data of individuals of European Union.
In conclusion, with the increase in cases of cybersecurity breaches, digital therapeutics shall focus on data protection not to lose trust and assure regulatory compliances. Because of these, issues that need to be dealt with assure growth of digital therapeutics in neurology.
The global neurology digital therapeutics industry recorded a CAGR of 8.2% during the historical period between 2019 and 2023. The growth of neurology digital therapeutics industry was positive as it reached a value of USD 226.8 million in 2023 from USD 155.3 million in 2019.
Neurology DTx development arose out of the wider digital health trends aimed at the increasing burden of neurological conditions. The earliest manifestations of these digital tools were often rudimentary, comprising basic symptom monitoring for migraine, epilepsy, and Alzheimer's disease.
Solutions in this early stage did face quite a few challenges related to accuracy, integration into healthcare systems, and low user adoption. Currently, the development of wearable technology, in concert with mobile apps and software algorithms, ushered in solutions that are more sophisticated.
Neurology-focused digital therapeutics gave way to remote monitoring, real-time data collection, and personalized intervention. As AI and machine learning mature, DTx platforms started to deploy predictive analytics in order to find early warning signals about the progression of the disease and maximize treatments using innovations based on patient-specific data.
As wearable devices and mobile health platforms become more sophisticated, DTx will increasingly provide continuous, remote patient management, reducing the need for in-person consultations and improving patient outcomes.
Principal Consultant
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 38.7% in global market. These companies are industry leaders with advanced technological capabilities, extensive research and development efforts, and strong financial resources.
They offer a wide array of wearable devices that monitor several health metrics-from simple measures complex neurological conditions and disease activity pattern. Prominent companies in tier 1 include Livongo Health, Noom, Omada Health, Pear Therapeutics and WellDoc.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 26.7% market share. The neurology digital therapeutics market is contributed to by tier 2 companies that have growing influence in the market. Most of the companies are focused on specific niche areas within the area of digital therapeutics and offer customized solutions for specific monitoring needs related to health.
A significant number of tier 2 companies focus on cost-effective solutions and strategic collaborations that increase their market reach. They invest in developing unique features and enhancing user experience with the sole aim of capturing segments of the market. Prominent companies in tier 2 include Proteus Digital Health, Propeller Health, Akili Interactive Labs and Mango Health.
Finally, Tier 3 companies, such as Better Therapeutics and Happify. They specialize in specific products and cater to niche markets, adding diversity to the industry. Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the neurology digital therapeutics sales remains dynamic and competitive.
The section below covers the industry analysis for the neurology digital therapeutics market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In Asia Pacific, India is projected to witness a CAGR of 8.0% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| China | 9.3% |
| India | 9.7% |
| USA | 2.3% |
| South Korea | 7.4% |
| Canada | 4.1% |
| Spain | 4.9% |
| Germany | 2.5% |
| France | 3.6% |
China neurology digital therapeutics market is poised to exhibit a CAGR of 9.3% between 2024 and 2034. Currently, it holds the highest share in the East Asian market, and the trend is expected to continue during the forecast period.
China is vigorously advancing in technology and is investing heavily in health innovation. Moreover, a large population and increasing health and wellness awareness bring demand forward for devices like health trackers, smartwatches, and other health monitoring devices. Added to this, some of the key technology companies and strong manufacturing are based in China. Due to this dominance China manufactures and supplies high-end neurology digital therapeutics for the market.
Additionally, China has a strong footprint in terms of its manufacturing base, which plays a leading role in the production of neurology digital therapeutics. Some of the major technology companies in the world are located here; most of these companies are on the leading edge in developing and manufacturing high-end wearable devices.
USA holds a significant market share in the neurology digital therapeutics, which can be attributed to its advanced healthcare infrastructure, high consumer spending power, and strong focus on health innovation. In addition, huge cases of neurological diseases and emphasis on preventive healthcare further add to the demand.
With increasing health awareness among American consumers, more rapidly growing adoption of these technologies has taken place for personal health monitoring and management.
American consumers have disposable incomes that are highly remarkable and have the potential to underpin mass diffusion in the market for the most recent health technologies, comprising wearable devices. The market persists in constant growth due to the willingness of consumers to part with money for digital therapeutics.
A blend of technological leadership and consumer demand, driven by a robust healthcare system, firmly establishes the lead of the USA in the neurology digital therapeutics market.
India’s Neurology Digital Therapeutics Market is poised to exhibit a CAGR of 9.7% between 2024 and 2034. Currently, it holds the highest share in the Asia Pacific market, and the trend is expected to continue during the forecast period.
The vast and health-conscious population of India has opened up growth opportunities in the neurology digital therapeutics market. The rapid urbanization and rise in disposable incomes are drivers of growth in demand for advanced digital therapeutics in healthcare across the country.
Government initiatives towards infrastructure in the healthcare sector, and towards promoting digital health technologies, further add strength to this market. Programs related to increasing access to healthcare and developing telemedicine have also been creating a better climate for wearable devices. With local manufacturers and tech companies coming into the market and providing cost-effective and innovative solutions that really work for Indian consumers, the prospects are bright.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section contains information about the leading segments in the industry. By Product, the software segment holds the highest market share of 43.7% in 2024.
| By Product | Software |
|---|---|
| Value Share (2024) | 43.7% |
In the Neurology DTx market, the software segment has emerged as the leading product category owing to its intrinsic characteristics of flexibility, scalability, and real-time, personalized care. Neurological conditions ranging from Alzheimer's, Parkinson's disease, multiple sclerosis, epilepsy, and migraine require constant monitoring and management, which the software solutions can do with efficiency.
These platforms, often available through mobile applications or cloud-based systems, work in active symptom monitoring from the perspective of both patients and healthcare providers, a cognitive assessment, and personalized treatment interventions.
For example: Pear Therapeutics’ reSET-O is used for condition called substance use disorder (SUD). Though primarily for addiction, reSET-O addresses the neurological aspects of opioid use disorder by using cognitive-behavioral therapy (CBT) delivered through a mobile app to manage cravings and relapse prevention. Software-driven DTx platforms are also capable of applying AI and ML for personalized interventions, disease progression monitoring, and real-time treatment optimization.
| By Indication | Diabetes |
|---|---|
| Value Share (2024) | 34.1% |
Diabetes segment has dominated the indication segment do to is high prevalence, thereby acquiring the significant share of 34.1%. Additionally, research has shown that cognitive decline is linked to type 2 diabetes, where diabetes becomes one of the contributing factors to dementia and Alzheimer's disease.
Digital therapeutics offer cognitive training, symptom monitoring, and lifestyle changes in terms of diet, physical activity, and management of one's mental health in order to reduce such risks. Some software platforms addressing brain health support better functioning of the brain and give diabetic patients a lesser chance of developing dementia.
Moreover, these patients are at an increased risk for stroke-which is one of the leading causes of neurological disability. Neurology DTx may help monitor cardiovascular health and encourage lifestyle modification that can reduce the risk of stroke. In addition, digital therapeutic platforms may contribute to stroke recovery with cognitive and motor rehabilitation programs.
The market players are imperatively employing strategic ways to compete and capture business shares, increasing product differentiation through innovation in product features, strategic collaboration with healthcare providers for product distribution, and looking for strategic partners who can support them in widening their product portfolios for global market reach.
These digital therapeutics, designed for neurological conditions also offer their users features that monitor physical activity, heart activity, sleep patterns, and expendable calories-keeping all of these factors in mind and driving the growing popularity of such devices. Such comprehensive monitoring definitely works in favor of deriving great insights into health and fitness levels, thereby making neurology digital therapeutics popular.
Recent Industry Developments in Neurology Digital Therapeutics Market
In terms of product, the industry is divided into software and devices.
In terms of indication, the industry is segregated into diabetes, obesity, cardiovascular, disease (CVD), central nervous system (CNS) disease, respiratory disease and others.
In the terms of end user, the market is segmented into hospital, clinics and others.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global neurology digital therapeutics market is projected to witness CAGR of 8.2% between 2024 and 2034.
The global neurology digital therapeutics industry stood at USD 226.8 million in 2023.
The global neurology digital therapeutics market is anticipated to reach USD 496.4 million by 2034 end.
India is set to record the highest CAGR of 9.7% in the assessment period.
The key players operating in the global neurology digital therapeutics market include Livongo Health, Noom, Omada Health, Pear Therapeutics, WellDoc, Proteus Digital Health, Propeller Health, Akili Interactive Labs, Mango Health, Better Therapeutics, Happify, Kaia Health and Click Therapeutics.
Explore Healthcare Insights
View Reports
Neurology Digital Therapeutics Market
